Q-omics provides the consensus-scored RN7SKP197 profile across patient tissues and cancer cell-line models. RN7SKP197 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RN7SKP197 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, RN7SKP197 RNA expression shows 13,479 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight CESC, LUSC, and CCRCC as cancer lineages where RN7SKP197 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP197 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP197 survival associations across molecular data types. RN7SKP197 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP197 RNA expression–survival associations across cancer types. High RN7SKP197 expression shows unfavorable associations in CESC, STAD and SKCM, but favorable associations in ESCA, LUAD and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RN7SKP197 RNA expression.
This table summarizes RN7SKP197 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP197. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP197 shows lower tumor expression in LUSC and COAD and higher tumor expression in KIRC. The LUSC box plot shows higher RN7SKP197 RNA expression in normal versus tumor tissue (log2 FC = −0.186, t-test p < 0.001).
This table shows molecular features associated with RN7SKP197 in patient tissues and cancer cell lines. In patient samples, RN7SKP197 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
